Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates
- 27 February 2020
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 26 (2), 282-289
- https://doi.org/10.1111/hae.13946
Abstract
The use of enhanced half‐life (EHL) FVIII has improved the quality of prophylaxis in haemophilia A, but with a benefit that may vary from one patient to another. We analysed the pharmacokinetic data obtained with efmoroctocog alfa (rFVIII‐Fc) in 114 patients and, in 47 cases, compared them to those previously measured with non‐EHL FVIII. The in vivo recovery (IVR) of rFVIII‐Fc measured with one stage clotting assay (OSA) and chromogenic assay (CSA) was 2.2 and 2.8 IU/mL per IU/kg, respectively. The median half‐life (T1/2) of rFVIII‐Fc was 14.5 hours whatever the FVIII:C assay used, but variable and correlated with preinfusion VWF:Ag levels (r = .76). Both IVR and T1/2 were lower in patients under 12 years old (2.4 IU/mL per IU/kg and 11.1 hours, respectively; CSA). PK study of rFVIII‐Fc vs non‐EHL FVIII showed a T1/2 ratio of 1.4 in favour of rFVIII‐Fc, regardless of the patient's age. However the relative increase in T1/2 with rFVIII‐Fc was lower than 30% in one‐third of patients evaluated, particularly when the previous FVIII administered was a BHK‐derived product. This study therefore suggests that analysis of individual PK profile in response to a specific FVIII concentrate is potentially useful before a switch in haemophilia A patients.Keywords
This publication has 20 references indexed in Scilit:
- Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?Journal of Thrombosis and Haemostasis, 2019
- Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasisBlood Reviews, 2019
- Defining extended half-life rFVIIIA critical review of the evidenceHaemophilia, 2018
- Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement TherapiesSeminars in Thrombosis and Hemostasis, 2017
- Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study ProtocolJMIR Research Protocols, 2016
- The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDOHaemophilia, 2016
- Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia AJournal of Thrombosis and Haemostasis, 2015
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood, 2014
- Measurement of factor VIII pharmacokinetics in routine clinical practiceJournal of Thrombosis and Haemostasis, 2012
- Clinical severity of haemophilia A: does the classification of the 1950s still stand?Haemophilia, 2011